At present, for NSCLC patients who are positive for EGFR gene mutations, using EGFR-TKI as the first-line treatment leads to better progression-free survival, especially in the Asia-Pacific region and Russia, where EGFR gene mutations are present in 49.3% of the total number of patients with NSCLC [28, 29]. Here, EGFR is linked to non-small cell lung carcinoma.